BioNTech SE (LTS:0A3M) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0A3M BioNTech SE LTS:0A3M
60 GF Score
Price $89.50
GF Value $84.44
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is BioNTech SE Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

BioNTech SE Valuation Rank Related Terms

LTS:0A3M
60GF Score
BioNTech SE LTS:0A3M
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is BioNTech SE (LTS:0A3M) Overvalued in 2026?

Based on GuruFocus' analysis, BioNTech SE stock appears to be overvalued. The current stock price of $89.50 is trading 6% above its estimated GF Value™ of $84.44. GuruFocus considers BioNTech SE to be Fairly Valued.

Key valuation signals for LTS:0A3M:

  • Valuation Rank:
  • GF Value™: $84.44 vs. price of $89.50 (6% above fair value)
  • GF Score™: 60/100 with 5 warning signs

No single metric tells the full story. See the LTS:0A3M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioNTech SE Business Description

Address An der Goldgrube 12, Mainz, RP, DEU, D-55131
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
60GF Score

Get the complete analysis for LTS:0A3M

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$89.50
Price
$84.44
GF Value